Literature DB >> 11523986

A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation.

G V De Ferrari1, M A Canales, I Shin, L M Weiner, I Silman, N C Inestrosa.   

Abstract

Acetylcholinesterase (AChE) has been found to be associated with the core of senile plaques. We have shown that AChE interacts with the amyloid beta-peptide (Abeta) and promotes amyloid fibril formation by a hydrophobic environment close to the peripheral anionic binding site (PAS) of the enzyme. Here we present evidence for the structural motif of AChE involved in this interaction. First, we modeled the docking of Abeta onto the structure of Torpedo californica AChE, and identified four potential sites for AChE-Abeta complex formation. One of these, Site I, spans a major hydrophobic sequence exposed on the surface of AChE, which had been previously shown to interact with liposomes [Shin et al. (1996) Protein Sci. 5, 42-51]. Second, we examined several AChE-derived peptides and found that a synthetic 35-residue peptide corresponding to the above hydrophobic sequence was able to promote amyloid formation. We also studied the ability to promote amyloid formation of two synthetic 24-residue peptides derived from the sequence of a Omega-loop, which has been suggested as an AChE-Abeta interacting motif. Kinetic analyses indicate that only the 35-residue hydrophobic peptide mimics the effect of intact AChE on amyloid formation. Moreover, RP-HPLC analysis revealed that the 35-residue peptide was incorporated into the growing Abeta-fibrils. Finally, fluorescence binding studies showed that this peptide binds Abeta with a K(d) = 184 microM, independent of salt concentration, indicating that the interaction is primarily hydrophobic. Our results indicate that the homologous human AChE motif is capable of accelerating Abeta fibrillogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11523986     DOI: 10.1021/bi0101392

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  54 in total

Review 1.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.

Authors:  Colin L Masters; Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

2.  Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations.

Authors:  Stevan Pecic; Marie A McAnuff; Wayne W Harding
Journal:  J Enzyme Inhib Med Chem       Date:  2010-06-28       Impact factor: 5.051

3.  Effect of long-term exposure to aluminum on the acetylcholinesterase activity in the central nervous system and erythrocytes.

Authors:  R R Kaizer; M C Corrêa; L R S Gris; C S da Rosa; D Bohrer; V M Morsch; Maria Rosa Chitolina Schetinger
Journal:  Neurochem Res       Date:  2008-05-10       Impact factor: 3.996

Review 4.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

Review 5.  Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Gohar Mushtaq; Nigel H Greig; Jalaluddin A Khan; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

6.  Synthesis and application of β-carbolines as novel multi-functional anti-Alzheimer's disease agents.

Authors:  William Horton; Abha Sood; Swarada Peerannawar; Nandor Kugyela; Aditya Kulkarni; Rekha Tulsan; Chris D Tran; Jessica Soule; Harry LeVine; Béla Török; Marianna Török
Journal:  Bioorg Med Chem Lett       Date:  2016-11-24       Impact factor: 2.823

7.  Butyrylcholinesterase attenuates amyloid fibril formation in vitro.

Authors:  Sophia Diamant; Erez Podoly; Assaf Friedler; Hagai Ligumsky; Oded Livnah; Hermona Soreq
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-26       Impact factor: 11.205

Review 8.  Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.

Authors:  Irene Bolea; Alejandro Gella; Mercedes Unzeta
Journal:  J Neural Transm (Vienna)       Date:  2012-12-13       Impact factor: 3.575

9.  Back-scattering interferometry: an ultrasensitive method for the unperturbed detection of acetylcholinesterase-inhibitor interactions.

Authors:  Gabrielle L Haddad; Sherri C Young; Ned D Heindel; Darryl J Bornhop; Robert A Flowers
Journal:  Angew Chem Int Ed Engl       Date:  2012-10-04       Impact factor: 15.336

Review 10.  Acetylcholinesterase in Hirschsprung's disease.

Authors:  S W Moore; G Johnson
Journal:  Pediatr Surg Int       Date:  2005-03-10       Impact factor: 1.827

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.